All In Biotech

Drug Trial Radar · NCT03762265

A Study of PRN1008 in Patients With Pemphigus

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor Rilzabrutinib (PRN1008) in Moderate to Severe Pemphigus

Last checked: Nov 20, 2026Latest source record: Aug 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

131

Actual

Start

Jan 8, 2019

Primary completion

Jul 30, 2021

Study completion Dec 17, 2021

Sponsor

Sponsor type
Industry
First posted
Dec 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (blinded treatment \[BT\] period) followed by an open-label extension \[OLE\] period intended to evaluate the efficacy and safety of oral PRN1008 in moderate to severe pemphigus. After completing the open-label extension period, eligible participants might continue in a long term extension (LTE) Period of 48 weeks.

Conditions

  • Pemphigus

Interventions

  • RilzabrutinibDrug

    Pharmaceutical form: Tablet Route of administration: Oral

  • PlaceboDrug

    Pharmaceutical form: Tablet Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved Complete Remission (CR) With a Corticosteroids Dose of Less Than or Equal to (<=) 10 mg/Day From Week 29 to Week 37: Pemphigus Vulgaris Participants in Modified Intent-to-Treat (PV mITT) PopulationTime frame: From Week 29 to Week 37
  2. Percentage of Participants Who Achieved Complete Remission With a Corticosteroids Dose of <=10 mg/Day From Week 29 to Week 37: Modified Intent-to-Treat (mITT) PopulationTime frame: From Week 29 to Week 37

Locations

88 sites in 19 countries. Site status is shown where the registry gives one.

  • Central Recruiting (Principia Biopharma)

    Boca Raton, Florida

  • Central Recruiting (Principia Biopharma)

    Coral Gables, Florida

  • Central Recruiting (Principia Biopharma)

    Atlanta, Georgia

  • Central Recruiting (Principia Biopharma)

    Ann Arbor, Michigan

  • Central Recruiting (Principia Biopharma)

    Ann Arbor, Michigan

  • Central Recruiting (Principia Biopharma)

    Rochester, Minnesota

  • Central Recruiting (Principia Biopharma)

    Albuquerque, New Mexico

  • Central Recruiting (Principia Biopharma)

    New York, New York

  • Central Recruiting (Principia Biopharma)

    New York, New York

  • Central Recruiting (Principia Biopharma)

    Chapel Hill, North Carolina

  • Central Recruiting (Principia Biopharma)

    Durham, North Carolina

  • Central Recruiting (Principia Biopharma)

    Cleveland, Ohio

  • Central Recruiting (Principia Biopharma)

    Austin, Texas

  • Central Recruiting (Principia Biopharma)

    Murray, Utah

  • Central Recruiting (Principia Biopharma)

    Buenos Aires, Argentina

  • Central Recruiting (Principia Biopharma)

    Buenos Aires, Argentina

  • Central Recruiting (Principia Biopharma)

    San Nicolás, Argentina

  • Central Recruiting (Principia Biopharma)

    Melbourne, Australia

  • Central Recruiting (Principia Biopharma)

    Sydney, Australia

  • Central Recruiting (Principia Biopharma)

    Fremantle, Western Australia, Australia

  • Central Recruiting (Principia Biopharma)

    Campinas, Brazil

  • Central Recruiting (Principia Biopharma)

    Campo Grande, Brazil

  • Central Recruiting (Principia Biopharma)

    Ribeirão Preto, Brazil

  • Central Recruiting (Principia Biopharma)

    Pleven, Bulgaria

  • Central Recruiting (Principia Biopharma)

    Plovdiv, Bulgaria

  • Central Recruiting (Principia Biopharma)

    Sofia, Bulgaria

  • Central Recruiting (Principia Biopharma)

    Winnipeg, Manitoba, Canada

  • Central Recruiting (Principia Biopharma)

    Osijek, Croatia

  • Central Recruiting (Principia Biopharma)

    Zagreb, Croatia

  • Central Recruiting (Principia Biopharma)

    Bobigny, France

  • Central Recruiting (Principia Biopharma)

    Bordeaux, France

  • Central Recruiting (Principia Biopharma)

    Lille, France

  • Central Recruiting (Principia Biopharma)

    Pierre-Bénite, France

  • Central Recruiting (Principia Biopharma)

    Rouen, France

  • Central Recruiting (Principia Biopharma)

    Toulouse, France

  • Central Recruiting (Principia Biopharma)

    Berlin, Germany

  • Central Recruiting (Principia Biopharma)

    Dresden, Germany

  • Central Recruiting (Principia Biopharma)

    Düsseldorf, Germany

  • Central Recruiting (Principia Biopharma)

    Erlangen, Germany

  • Central Recruiting (Principia Biopharma)

    Heidelberg, Germany

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.